Analyst Price Targets — CALC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 20, 2024 6:51 am | Leland Gershall | Oppenheimer | $14.00 | $5.45 | StreetInsider | Oppenheimer Reiterates Outperform Rating on CalciMedica (CALC) |
| November 22, 2022 2:31 pm | Christopher Raymond | Raymond James | $392.00 | $146.90 | TheFly | Piper Sandler keeps Neutral on Graybug Vision following CalciMedica merger news |
| May 18, 2022 9:13 pm | Christopher Raymond | Piper Sandler | $392.00 | $171.81 | TheFly | Graybug Vision price target lowered to $2 from $4 at Piper Sandler |
Latest News for CALC
LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock,…
FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a strategy to evaluate elevated lactate dehydrogenase (LDH) as a potential enrichment marker for identifying patients at increased risk of new-onset severe respiratory failure LA JOLLA, Calif., July 29, 2026 /PRNewswire/ --…
Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H 2027 with upfront proceeds LA JOLLA, Calif., June 24, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the…
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue clinical development of Auxora across indications LA JOLLA, Calif., June 24, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CALC.
U.S. House Trading
No House trades found for CALC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.